Overview

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced nephropathy. In a sub-group of patients coronary flow reserve will be evaluated.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Suleyman Demirel University
Treatments:
Acetylcysteine
N-monoacetylcystine
Criteria
Inclusion Criteria:

- Patients with Acute ST Elevation Myocardial Infarction undergoing Primary Percutaneous
Coronary intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy
(Mehran Score ≥5)

Exclusion Criteria:

- Patients >18 years old with moderate to high risk for contrast induced nephropathy
undergoing percutaneous coronary intervention

- Low risk for contrast induced nephropathy (Mehran Score <5)

- Use of nephrotoxic agents (NSAIDs, aminoglycosides,recent contrast injection...)

- Infection

- Pregnancy, Lactation

- Renal failure requiring dialysis

- Hepatic failure

- Allergy to NAC

- History of Asthma

- Chronic nitrate usage

- Malignancy

- Use of corticosteroids

- Leucocytosis,Thrombocytosis,Anemia

- Blood pressure of >180/100mmHg despite anti-hypertensive therapy